Sun Pharmaceutical Industries, Inc. is recalling approximately 207,969 units of Sumatriptan Succinate Tablets (50 mg and 100 mg), commonly used to treat migraine headaches. The recall was initiated because routine testing revealed that certain lots did not meet chemical impurity and degradation specifications, meaning the medication contained higher-than-allowed levels of related substances. Consumers should check their prescription bottles or blister packs for the specific lot numbers and expiration dates affected by this recall. You should contact your doctor or pharmacist to discuss your treatment and how to obtain a safe replacement.
The tablets failed to meet quality standards for impurities and degradation, which could potentially reduce the effectiveness of the medication or expose patients to unexpected substances resulting from chemical breakdown.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.